|
|
|
|
|
| Interview |
 |
|
Ready to Rise in Russia |
Matthias Wernicke, General Manager of Merck KGaA's Biopharma business in Russia, talks about how the country is transitioning from an emerging to a mature pharmaceutical market.
… /Read more/ |
|
|
|
| Audio |
 |
|
|
|
| Industry update |
| //
Bruntwood SciTech announced that Dr. Kath Mackay was appointed to its leadership team as Managing Director, Alderley Park, the UK's largest single-site life science campus.
//
Immuno-oncology company Immodulon (Uxbridge, UK) appointed Professor Bams Abila, M.D., Ph.D., FFPM, as Chief Medical Officer.
//
Kymab (Cambridge, UK) appointed Catherine Moukheibir as a Non-Executive Director.
//
Vaccitech (Oxford, UK) appointed Mariem Charafeddine as Chief Medical Officer.
//
Rafarma Pharmaceuticals (Ljubljana, Slovenia) named Vladimir Dolgolenko as its new CEO and President.
//
Cristal Therapeutics (Maastricht, The Netherlands) named Dr. Werner Cautreels as Board Chairman and Andre Verwei as Chief Financial Officer.
//
Entera Bio (Jerusalem, Israel) announced the appointment of Adam Gridley as Chief Executive Officer. Phillip Schwartz, Ph.D., former CEO of Entera, will continue as President of Research & Development and Executive Vice President at Entera.
//
Protalix BioTherapeutics (Carmiel, Israel) announced that Eyal Rubin has been appointed to serve as the company's new Senior Vice President and Chief Financial Officer, effective September 22, 2019.
|
|
|
|
|
|
|
|
|
